AS
IDXG

Arxis Securities’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Arxis Securities’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$96K Buy
+3,640
New +$130K 0.51% 42

Other funds holding IDXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
TDC
Thompson Davis & Co Richmond, Virginia $150M AUM 32.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Arxis Securities's IDXG Position: Q1 2017 in Review

Arxis Securities opened a new position in Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2017: 3,640 shares worth $96K. The stake represents 0.51% of the portfolio and ranks #42 among its holdings.

16 funds tracked by Wall St. Rank hold IDXG as of Q1 2017.

  • Arxis Securities held 3,640 shares of Interpace Biosciences, Inc. Common Stock worth $96K as of Q1 2017.
  • Interpace Biosciences, Inc. Common Stock was a new Arxis Securities position in Q1 2017.
  • Interpace Biosciences, Inc. Common Stock made up 0.51% of Arxis Securities's portfolio in Q1 2017, its #42 holding.
  • 16 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2017.

Based on Arxis Securities's 13F filing for Q1 2017, filed 8 May 2017.